The quantum rally is about to get a price tag it cannot ignore. Honeywell-backed Quantinuum is selling 21 million shares at $45–$50 — up to $1.05 billion raised at a valuation near $12.7 billion — while its latest quarter shows $5.2 million of revenue and a $136.6 million net loss.
| Metric | Value |
|---|---|
| Valuation | ~$12.7B (top of range) |
| Price range | $45–$50, ticker QNT |
| Q1 2026 revenue | $5.2M (down from $19.1M YoY) |
| Q1 net loss | $136.6M |
| 2025 bookings | $79.3M |
| Honeywell votes post-IPO | ~49% |
| Sector since Mar 30 | IONQ +132%, QBTS +110%, RGTI +85% |
Why it moved
The quantum complex has been the most speculative corner of this market — IonQ up 132% in ten weeks, D-Wave and Rigetti not far behind. Quantinuum is arguably the most credible private asset in the space (Honeywell's hardware plus Cambridge Quantum's software), which is exactly why this IPO is a stress test: a real institutional book will now have to underwrite a $12.7 billion valuation against $5.2 million of quarterly revenue — roughly 600x annualized sales. Either the book validates the public comps, or it reprices them.
What it means for you
If QNT prices at the top and trades up, the whole sector gets a fresh momentum leg. If it struggles, the read-through hits IONQ, RGTI and QBTS hardest — they are priced off the same faith with less institutional backing. Note the revenue went down year over year; this is pre-commercial technology trading on milestones, not earnings.
Bottom line: I treat quantum as a lottery-ticket allocation, never a core position — and I would rather watch how institutions price QNT than front-run them. The IPO will tell us more about the sector in one week than the charts told us in six months.